Hepatab 200 mg (Tablet)
Unit Price: ৳ 20.00 (2 x 10: ৳ 400.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Ibn sina pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase.
Dosage & Administration
- Traveler's Diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years)
- Hepatic Encephalopathy: 550 mg 2 times daily (patients ≥18 years)
- Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days (can be taken with or without food)
Interaction
Hepatab induces CYP3A4 in vitro; however, at recommended dosing regimen, it is not expected to induce CYP3A4 in patients with normal liver function.
Contraindications
Hypersensitivity to Rifaximin or any rifamycin antimicrobial agents, or any components of the product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C; unknown excretion in human milk
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Discontinue treatment if diarrhea symptoms worsen or persist for more than 24-48 hours
- Consider alternative antibiotic therapy if diarrhea worsens
- Consider pseudomembranous colitis diagnosis in patients with diarrhea
Use in Special Populations
- Renal Impairment: Pharmacokinetics not studied in patients with impaired renal function
- Hepatic Impairment: Markedly elevated systemic exposure in patients with hepatic impairment compared to healthy subjects
Overdose Effects
No specific information available on treatment of overdose; discontinue Hepatab and institute supportive measures
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture; keep out of the reach of children